Tofacitinib

Drug Details

Tofacitinib, marketed as Xeljanz, is a medication primarily used to manage various types of arthritis in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is also prescribed for moderate-to-severe ulcerative colitis and for treating moderate-to-severe polyarticular juvenile idiopathic arthritis in children aged 2 years and older. As a Janus kinase (JAK) inhibitor, tofacitinib works by blocking the JAK proteins in the body, which are responsible for promoting inflammation. By inhibiting these proteins, tofacitinib effectively reduces inflammation, leading to decreased pain, tenderness, and swelling in the joints, as well as alleviating symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Tofacitinib is typically administered orally once or twice daily, suitable for patients who have not responded adequately to other treatments. However, it is important to be aware of potential side effects, including an increased risk of infections, headaches, diarrhea, and more serious risks like heart issues and blood clots. Always consult with a healthcare provider before starting any new medication to ensure it is safe and appropriate for your specific health needs.